News >

Pembrolizumab Plus Lenvatinib Trial in Endometrial Carcinoma Expanded

Jason Harris
Published: Wednesday, Sep 06, 2017

The phase Ib/II Study 111 examining the combination of pembrolizumab (Keytruda) and lenvatinib (Lenvima) in women with metastatic endometrial carcinoma has been expanded based on positive interim results, according to Eisai, the manufacturer of lenvatinib.

Endometrial carcinoma is the sixth most common cancer in women worldwide, with 320,000 new cases diagnosed in 2012. In the United States, it is estimated that there will be 60,000 new cases and 10,000 deaths attributed to the disease in 2017. There currently is no drug approved for second-line therapy.
Makker V, Rasco DW, Dutcus CE, et al. A phase Ib/II trial of lenvatinib (LEN) plus pembrolizumab (Pembro) in patients (Pts) with endometrial carcinoma. J Clin Oncol. 2017;35 (suppl; abstr 5598).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x